Pol Specenier

5.0k total citations
84 papers, 1.9k citations indexed

About

Pol Specenier is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Otorhinolaryngology. According to data from OpenAlex, Pol Specenier has authored 84 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 55 papers in Oncology, 39 papers in Pulmonary and Respiratory Medicine and 32 papers in Otorhinolaryngology. Recurrent topics in Pol Specenier's work include Head and Neck Cancer Studies (32 papers), Lung Cancer Treatments and Mutations (26 papers) and Peptidase Inhibition and Analysis (13 papers). Pol Specenier is often cited by papers focused on Head and Neck Cancer Studies (32 papers), Lung Cancer Treatments and Mutations (26 papers) and Peptidase Inhibition and Analysis (13 papers). Pol Specenier collaborates with scholars based in Belgium, United States and Italy. Pol Specenier's co-authors include Jan B. Vermorken, Jan B. Vermorken, Filip Lardon, Jan B. Vermorken, Marc Baay, Vanessa Deschoolmeester, Marc Peeters, Ilse Weets, Christophe De Block and An Wouters and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Pol Specenier

81 papers receiving 1.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Pol Specenier Belgium 21 1.1k 624 542 450 287 84 1.9k
Panagiota Economopoulou Greece 26 1.4k 1.3× 891 1.4× 597 1.1× 297 0.7× 277 1.0× 105 2.7k
Xue Hou China 26 1.3k 1.2× 376 0.6× 1.0k 1.9× 251 0.6× 387 1.3× 104 2.1k
Hendrik A. Wolff Germany 31 1.2k 1.1× 632 1.0× 835 1.5× 573 1.3× 828 2.9× 106 2.6k
Andrew C. Birkeland United States 27 533 0.5× 626 1.0× 505 0.9× 569 1.3× 544 1.9× 116 2.0k
Paolo Muto Italy 21 789 0.7× 387 0.6× 664 1.2× 185 0.4× 277 1.0× 117 1.7k
Thomas J. Ow United States 23 695 0.6× 714 1.1× 384 0.7× 514 1.1× 654 2.3× 87 2.0k
Stefan Kasper Germany 24 885 0.8× 636 1.0× 397 0.7× 110 0.2× 268 0.9× 122 2.0k
M Francoual France 28 1.5k 1.4× 729 1.2× 682 1.3× 319 0.7× 251 0.9× 60 2.2k
Sang‐Hue Yen Taiwan 23 512 0.5× 390 0.6× 315 0.6× 194 0.4× 352 1.2× 52 1.8k
Ngan‐Ming Tsang Taiwan 31 955 0.9× 459 0.7× 450 0.8× 839 1.9× 748 2.6× 88 2.3k

Countries citing papers authored by Pol Specenier

Since Specialization
Citations

This map shows the geographic impact of Pol Specenier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pol Specenier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pol Specenier more than expected).

Fields of papers citing papers by Pol Specenier

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pol Specenier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pol Specenier. The network helps show where Pol Specenier may publish in the future.

Co-authorship network of co-authors of Pol Specenier

This figure shows the co-authorship network connecting the top 25 collaborators of Pol Specenier. A scholar is included among the top collaborators of Pol Specenier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pol Specenier. Pol Specenier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Specenier, Pol, et al.. (2021). A rare case of primary mucosal melanoma involving the oropharynx. SHILAP Revista de lepidopterología. 17(3). 201–208.
2.
Winter, Benedicte Y. De, Kevin Lamote, Jan P. van Meerbeeck, et al.. (2020). A Literature Review of the Potential Diagnostic Biomarkers of Head and Neck Neoplasms. Frontiers in Oncology. 10. 1020–1020. 20 indexed citations
3.
Bossche, Jolien Van den, Andreas Domen, Marc Peeters, et al.. (2019). Radiosensitization of Non-Small Cell Lung Cancer Cells by the Plk1 Inhibitor Volasertib Is Dependent on the p53 Status. Cancers. 11(12). 1893–1893. 9 indexed citations
4.
Specenier, Pol. (2018). Nivolumab in squamous cell carcinoma of the head and neck. Expert Review of Anticancer Therapy. 18(5). 409–420. 7 indexed citations
5.
Specenier, Pol, Éva Remenár, Jan Buter, et al.. (2017). TPF plus cetuximab induction chemotherapy followed by biochemoradiation with weekly cetuximab plus weekly cisplatin or carboplatin: a randomized phase II EORTC trial. Annals of Oncology. 28(9). 2219–2224. 12 indexed citations
6.
Specenier, Pol. (2017). Pembrolizumab use for the treatment of advanced melanoma. Expert Opinion on Biological Therapy. 17(6). 765–780. 9 indexed citations
7.
Specenier, Pol & Jan B. Vermorken. (2016). Afatinib in squamous cell carcinoma of the head and neck. Expert Opinion on Pharmacotherapy. 17(9). 1295–1301. 15 indexed citations
8.
Specenier, Pol. (2016). Ipilimumab in melanoma. Expert Review of Anticancer Therapy. 16(8). 811–826. 30 indexed citations
9.
Boeckx, Carolien, Ken Op de Beeck, Ridha Limame, et al.. (2015). Establishment and characterization of cetuximab resistant head and neck squamous cell carcinoma cell lines: focus on the contribution of the AP-1 transcription factor.. PubMed Central. 5(6). 1921–38. 24 indexed citations
10.
Paepe, A. De, et al.. (2015). Medical Cost Associated with Treatment and Follow-Up of Pantients with Head and Neck Cancer. Value in Health. 18(7). A449–A449. 2 indexed citations
11.
Paepe, A. De, et al.. (2015). Cost and Cost-Effectiveness Data on Pancreatic Cancer: a Comprehensive Review of the Literature. Value in Health. 18(7). A448–A449. 1 indexed citations
12.
Szturz, Petr, Pol Specenier, Carl Van Laer, et al.. (2015). Long-term remission of locally recurrent oropharyngeal cancer after docetaxel-based chemotherapy plus cetuximab. European Archives of Oto-Rhino-Laryngology. 273(6). 1629–1636. 4 indexed citations
13.
Machiels, J.-P., Pol Specenier, John C. Krauss, et al.. (2015). A proof of concept trial of the anti-EGFR antibody mixture Sym004 in patients with squamous cell carcinoma of the head and neck. Cancer Chemotherapy and Pharmacology. 76(1). 13–20. 21 indexed citations
14.
Nuffelen, Gwen Van, Leen Van den Steen, Olivier M. Vanderveken, et al.. (2015). Study protocol for a randomized controlled trial: tongue strengthening exercises in head and neck cancer patients, does exercise load matter?. Trials. 16(1). 395–395. 22 indexed citations
15.
Boeckx, Carolien, Christine Weyn, Isabelle Vanden Bempt, et al.. (2014). Mutation analysis of genes in the EGFR pathway in Head and Neck cancer patients: implications for anti-EGFR treatment response. BMC Research Notes. 7(1). 337–337. 27 indexed citations
16.
Specenier, Pol, et al.. (2013). Cetuximab: its unique place in head and neck cancer treatment. Biologics. 7. 77–77. 71 indexed citations
17.
18.
Specenier, Pol & Jan B. Vermorken. (2010). Advances in the systemic treatment of head and neck cancers. Current Opinion in Oncology. 22(3). 200–205. 16 indexed citations
19.
Specenier, Pol, Marika Rasschaert, Jan Van den Brande, et al.. (2010). Docetaxel, ifosfamide and cisplatin in solid tumour treatment: a phase I study. Anti-Cancer Drugs. 21(3). 306–312. 1 indexed citations
20.
Specenier, Pol & Jan B. Vermorken. (2010). Targeted Therapy in Combination with Chemotherapy in Recurrent and/or Metastatic Head and Neck Cancer. European Oncology & Haematology. 6(1). 43–43.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Panagiota Economopoulou Breakdown of academic impact, for papers by Xue Hou Breakdown of academic impact, for papers by Hendrik A. Wolff Breakdown of academic impact, for papers by Andrew C. Birkeland Breakdown of academic impact, for papers by Paolo Muto Breakdown of academic impact, for papers by Thomas J. Ow Breakdown of academic impact, for papers by Stefan Kasper Breakdown of academic impact, for papers by M Francoual Breakdown of academic impact, for papers by Sang‐Hue Yen Breakdown of academic impact, for papers by Ngan‐Ming Tsang
Rankless by CCL
2026